1. Renin-angiotensin system in osteoarthritis: A new potential therapy
   Yuangang Wu et al, 2019, International Immunopharmacology CrossRef
2. null
   Kamal Bali et al, 2020 CrossRef
3. Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway
   Amany A. Azouz et al, 2020, Saudi Pharmaceutical Journal CrossRef
4. Mechanisms Involved in Superiority of Angiotensin Receptor Blockade over ACE Inhibition in Attenuating Neuropathic Pain Induced in Rats
   Nora Hegazy et al, 2020, Neurotherapeutics CrossRef
5. Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression
   Jesús Seco-Calvo et al, 2020, Bone & Joint Research CrossRef
6. Angiotensin II triggers knee joint lesions in experimental osteoarthritis
   Grazielle A. de Sá et al, 2021, Bone CrossRef
7. Hypertension meets osteoarthritis - revisiting the vascular aetiology hypothesis.
   Chunyi WEN, 0 CrossRef
8. Pharmaceutical therapeutics for articular regeneration and restoration: state-of-the-art technology for screening small molecular drugs
   Yishan Chen et al, 2021, Cell. Mol. Life Sci. CrossRef
9. Mechanisms and Molecular Targets of BuShenHuoXue Formula for Osteoarthritis
   Wen Xiong et al, 2022, ACS Omega CrossRef
10. Promising results of captopril in improving knee arthrofibrosis and cartilage status: an animal model study
    Seyed Ali Hashemi et al, 2022, J EXP ORTOP CrossRef
11. Molecular Basic of Pharmacotherapy of Cytokine Imbalance as a Component of Intervertebral Disc Degeneration Treatment
    Natalia A. Shnayder et al, 2023, IJMS CrossRef
12. Advanced Progress of the Relationship Between Antihypertensive Drugs and Bone Metabolism
    Ruixing Zhang et al, 2023, Hypertension CrossRef